This document is NOT medical advice. Neurofibromatosis requires specialist management (neurology, oncology, ophthalmology, genetics). Do NOT stop prescribed medications or delay cancer surveillance. MPNSTs are life-threatening and require IMMEDIATE oncology evaluation. All protocols are adjunctive to specialist NF management. Not FDA approved. © 2026 Joshua Farrior / Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Table of Contents
Overview — Three NF Disorders, Multi-Node Pathway Suppression
Neurofibromatosis encompasses three genetically distinct tumor predisposition syndromes. NF1 (1 in 3,000; neurofibromin/RAS-GAP) causes neurofibromas, plexiform tumors, and an 8-13% lifetime MPNST risk. NF2 (1 in 25,000; merlin/Hippo pathway) causes bilateral vestibular schwannomas with progressive hearing loss. Schwannomatosis (1 in 40,000; SMARCB1/LZTR1) is defined primarily by chronic severe pain. No cure exists for any of the three; FDA approval of selumetinib for NF1 in 2020 demonstrated that downstream signaling is pharmacologically addressable.
RAS/MAPK Coherence Collapse
Neurofibromin is a RAS-GAP — the molecular coherence gate for neural crest proliferation. Loss drives constitutive RAS → MAPK/ERK + PI3K/mTOR signaling. Protocol: multi-node pathway suppression through curcumin (upstream) + quercetin (midstream) + resveratrol (downstream mTOR).
Hippo Pathway / Contact Inhibition Loss
Merlin activates Hippo pathway — enforcing contact inhibition and density coherence. Loss drives schwannoma and meningioma formation. Protocol: resveratrol (NF2-specific evidence — Giovannini 2014); hearing preservation PBM; bevacizumab compatible.
Pain-First Protocol
Defined by chronic severe pain — often refractory to standard analgesics. Protocol priority: LDN 4.5 mg nightly + alpha-lipoic acid + 174 Hz pain gate + PBM over painful territories + modified coherence lock 4-6× daily. Pain reduction is the primary endpoint.
The Christos™ framework proposes NF is a neural coherence architecture disorder. This paper uses 'management' — not 'reversal' — reflecting the genetic reality. The protocol targets tumor growth rate reduction, pain reduction, and hearing stability through 14 modalities. Thirteen falsifiable predictions are provided. Proprietary specifications available under NDA.
Three Disorders, One Coherence Framework
| Feature | NF1 | NF2 | Schwannomatosis |
|---|---|---|---|
| Gene / Protein | NF1 / Neurofibromin (RAS-GAP) | NF2 / Merlin (Hippo pathway) | SMARCB1 or LZTR1 |
| Prevalence | 1 in 3,000 | 1 in 25,000 | 1 in 40,000 |
| Primary tumors | Cutaneous + plexiform neurofibromas; optic gliomas; MPNSTs | Bilateral vestibular schwannomas; spinal schwannomas; meningiomas | Multiple schwannomas (NOT bilateral vestibular); pain-dominant |
| Primary burden | Tumor burden; disfigurement; pain; MPNST risk 8-13% lifetime | Hearing loss; tinnitus; balance problems; facial nerve dysfunction | Chronic severe pain — primary presenting symptom |
| FDA-approved treatment | Selumetinib (Koselugi, 2020) for pediatric plexiform NF; surgery | Bevacizumab off-label; surgery; stereotactic radiosurgery | Surgery; pain management — no FDA-approved drug |
| C_neural threshold | ≤ 0.45 (active plexiform growth) | ≤ 0.40 (bilateral schwannomas) | ≤ 0.50 (more limited coherence collapse) |
MPNST WARNING: 8-13% lifetime MPNST risk in NF1; 5-year survival 20-50%; leading cause of NF1 mortality. Any rapidly growing, newly painful, or consistency-changing mass in NF1 requires IMMEDIATE oncology evaluation. Annual whole-body MRI (WB-MRI) is mandatory surveillance.
The Coherence Architecture of RAS/MAPK and Hippo Pathways
| Gene Product | Coherence Function | Coherence Collapse Consequence | Protocol Response |
|---|---|---|---|
| Neurofibromin (NF1) | RAS-GAP — gates neural crest cell proliferation; turns off RAS after growth signal | Constitutive RAS-MAPK-ERK + PI3K-mTOR activation; progressive neurofibroma accumulation | Curcumin (RAS processing) + quercetin (PI3K) + resveratrol (mTOR) — three-node suppression |
| Merlin (NF2) | Hippo pathway activator — enforces contact inhibition; maintains cell density coherence | Loss of contact inhibition; schwannoma and meningioma formation; constitutive mTOR | Resveratrol (Giovannini 2014 NF2 evidence); curcumin; bevacizumab compatible |
| SNF5/SMARCB1 | Chromatin remodeling — maintains epigenetic coherence of neural crest identity | Neural crest identity loss; pain-generating schwannomas | Full protocol with pain emphasis; SMARCB1 loss also seen in some MPNSTs — surveillance critical |
The 14-Modality NF Coherence Protocol
2.1 Protocol Matrix
| # | Modality | Phase 0 | Phase 1 (Wks 1-12) | Phase 2 (Wks 13-24) | Phase 3 (Wks 25-52) | Phase 4 (Wk 53+) |
|---|---|---|---|---|---|---|
| 1 | Specialist surveillance | Baseline imaging | Continue per specialist | Annual minimum | Annual | Annual + PRN |
| 2 | Selumetinib (if prescribed) | Continue | Continue | Continue | Per oncologist | Per oncologist |
| 3 | Curcumin BCM-95 | 2 g/day | 2-4 g/day | 2-4 g/day | 1-2 g/day | 1-2 g/day |
| 4 | Resveratrol micronized | 500 mg/day | 500-1000 mg/day | 500-1000 mg/day | 500 mg/day | 500 mg/day |
| 5 | Quercetin | 500 mg/day | 500-1000 mg/day | 500-1000 mg/day | 500 mg/day | 500 mg/day |
| 6 | LDN (pain; NF2; schwannomatosis) | — | 1.5-4.5 mg nightly | 3.0-4.5 mg nightly | Maintain | Continue |
| 7 | Alpha-lipoic acid R-ALA | 600 mg/day | 600-1200 mg/day | 1200 mg/day | 600 mg/day | 600 mg/day |
| 8 | Christos™ NeuroFlux-NF | — | 30 mL 2× daily | 30 mL 3× daily | 30 mL 2× daily | 30 mL 2× daily |
| 9 | Transcranial/neural PBM 850 nm | — | 5× weekly | 5× weekly | 3-5× weekly | 3× weekly |
| 10 | PEMF 7.83+528 Hz | — | 2× daily 30 min | 2× daily | 1× daily | 1× daily |
| 11 | NCC-1 Chamber | — | 3× weekly | 3-5× weekly | 2× weekly | 1-2× weekly |
| 12 | NeuroBand | — | 24/7 | 24/7 | Overnight | 5 nights/week |
| 13 | Modified coherence lock (NO HOLD) | 3× daily | 3× daily | 3× daily | 2× daily | 1-2× daily |
| 14 | Vitamin D3 + omega-3 + NAC | Begin immediately | Full doses | Full doses | Maintenance | Continue |
2.2 RAS/MAPK/mTOR Three-Node Suppression
| Agent | Pathway Node | NF Evidence | Rationale vs. Selumetinib |
|---|---|---|---|
| Curcumin BCM-95 (2-4 g/day) | RAS farnesylation (upstream); NF-κB; direct anti-proliferative in NF1-null Schwann cells | Ly 2010 — reduces neurofibroma growth in NF1 mouse model; BCM-95 6.93× bioavailability | Targets RAS processing upstream of MEK — complementary node to selumetinib |
| Resveratrol micronized (500-1000 mg/day) | mTOR via AMPK (downstream); NF2 schwannoma growth; SIRT1 epigenetic | Giovannini 2014 — reduces NF2 schwannoma growth; Bhatt 2018 NF1 models | mTOR — downstream convergence of both NF1 and NF2 pathways; not targeted by selumetinib |
| Quercetin (500-1000 mg/day) | PI3K (midstream); VEGF reduction; anti-proliferative in schwannoma cell lines | Multiple in vitro studies; PI3K inhibition well-documented | PI3K sits between RAS and mTOR — creates three-node simultaneous pathway suppression |
Multi-node rationale: curcumin (RAS upstream) + quercetin (PI3K midstream) + resveratrol (mTOR downstream) creates three-point simultaneous suppression of the same pathway selumetinib targets at a single MEK node. Prediction NF-4 tests additive effect with selumetinib in pediatric NF1.
NO BREATH-HOLD in NF patients with spinal tumors, cord compression, or balance impairment from vestibular schwannomas. Pursed-lip adapted coherence lock throughout all phases — same modification as GBM and COPD protocols.
Type-Specific Priorities
3.1 NF1 — Plexiform Suppression and MPNST Prevention
| Priority | Protocol Specification |
|---|---|
| Plexiform neurofibroma suppression | Full RAS/mTOR stack; NeuroFlux-NF 3× daily; selumetinib if oncologist prescribes (compatible with coherence protocol); annual WB-MRI mandatory |
| MPNST surveillance | Annual whole-body MRI; immediate oncology referral for rapid growth, new pain, or consistency change — MPNST risk is real and primary mortality cause |
| Optic pathway glioma (NF1) | Annual ophthalmology; visual acuity monitoring; systemic curcumin + resveratrol; PBM periorbital with ophthalmologist clearance |
| Cognitive support (NF1-associated) | Omega-3 DHA 2-3 g/day; lion's mane extract (NGF); PEMF 7.83 Hz; NeuroBand overnight |
3.2 NF2 — Hearing Preservation Protocol
| Priority | Protocol Specification |
|---|---|
| Vestibular schwannoma suppression | Resveratrol 1000 mg/day (Giovannini 2014 — NF2-specific evidence); curcumin 4 g/day; bevacizumab if prescribed (compatible); everolimus off-label per physician |
| Hearing preservation | Retroauricular PBM (850 nm, 5 J/cm2, 5× weekly); NeuroFlux-NF NAC + DHA + citicoline cochlear neuroprotection; avoid ototoxic agents where possible |
| Balance rehabilitation | Vestibular PT 2-3× weekly (essential, not replaceable by coherence protocol); PEMF 7.83 Hz neural circuit stabilization |
| Post-acoustic neuroma surgery | Pre-op: PBM 850 nm retroauricular 5× weekly × 4 weeks; Post-op from day 3; NeuroFlux-NF citicoline + lion's mane for facial nerve regeneration support |
3.3 Schwannomatosis — Pain-First Protocol
Pain is the primary strategic goal — chronic, severe, often refractory to standard analgesics. Protocol priority: LDN 4.5 mg nightly (maximum dose — pain is the primary indication); alpha-lipoic acid 1200 mg/day; magnesium glycinate 800 mg/day; PBM 850 nm over each painful schwannoma territory; 174 Hz continuous audio during pain episodes; modified coherence lock 4-6× daily. Use validated pain scales (NRS 0-10, Brief Pain Inventory) weekly — pain reduction is the primary efficacy endpoint for schwannomatosis.
Christos™ Fluid and Device Platform — Overview
Complete formulations, device specifications, crystal array configurations, and manufacturing details are proprietary and available under NDA. Contact christosenergy.com for licensing inquiries.
4.1 Christos™ NeuroFlux-NF — Oral Coherence Fluid
NeuroFlux-NF targets three simultaneous NF dimensions: RAS/mTOR pathway suppression, neural coherence field restoration in neural crest tissue, and pain modulation. Key evidence-based agents: Curcumin BCM-95 liposomal (RAS farnesylation; NF1 mouse model — Ly 2010); Resveratrol micronized trans (mTOR/AMPK; NF2 schwannoma model — Giovannini 2014); Quercetin (PI3K inhibition; VEGF reduction); DHA high-dose algal (neural membrane coherence; anti-neuroinflammatory); Citicoline (neuroprotection for compressed nerves; cochlear protection in NF2; Saver 2008 Cochrane); Lion's mane extract (NGF stimulation — erinacines cross BBB; facial nerve regeneration; Mori 2009 RCT); Alpha-lipoic acid R-ALA (neuropathic pain — Ziegler 2011 RCT; nerve antioxidant); NAC (glutathione restoration; oxidative stress in tumor-compressed neural tissue); Magnesium L-threonate (NMDA modulation; superior BBB penetrance; central pain); CoQ10 ubiquinol (mitochondrial restoration in compressed neural tissue).
24-hour imprinting: 174 Hz (3hr pain gate) + 285 Hz (2hr neural regeneration) + 396 Hz (3hr RAS pattern release; immune reset) + 417 Hz (2hr debris clearing) + 528 Hz (8hr primary healing; mTOR suppression coherence; longest window) + 639 Hz (2hr neural network communication) + 741 Hz (2hr NGF pathway restoration) + 852 Hz (2hr Schwann cell identity awakening). Dosage: 30 mL 3× daily Phase 2; 30 mL 2× daily otherwise.
NeuroFlux-NF — Complete formulation: exact agent amounts, preparation protocol, imprinting cycle specifications, QC testing. Available under NDA — christosenergy.com
4.2 NCC-1 Neural Coherence Chamber — NF Configuration
PEMF (7.83+528 Hz); transcranial + peripheral nerve territory PBM arrays (850+660 nm, adjustable positioning for tumor sites); 5-phase Solfeggio acoustic (174 Hz extended for pain — 15 min; phases through 963 Hz); NeuroFlux-NF nebulization 1 mL/min throughout; 48 crystal nodes (amethyst × 24 primary for neural frequency range; clear quartz × 24 supplementary). Sessions 75-90 min (90 min for schwannomatosis pain emphasis), 3-5× weekly.
NCC-1 NF Configuration — Complete device specifications: PEMF array, PBM fields, 48-node crystal placement, nebulization specs, manufacturing details. Available under NDA
4.3 Christos™ NeuroBand — NF Adaptation
12-node adjustable headband (amethyst × 8 primary, clear quartz × 4); EEG-aligned placement: F3/F4 (cognitive support NF1), T3/T4 (vestibular schwannoma territory NF2), C3/C4 (motor zones), Cz (central integration). Frequencies: 174+285+528+741 Hz cycling. 24/7 Phase 1-2; overnight Phase 3-4. NF2 post-surgical: begin only after wound healed (3-4 weeks); neurosurgeon clearance required before initiating.
NeuroBand NF — Crystal specifications, frequency parameters, manufacturing specifications. Available under NDA
Falsifiable Predictions — 13 Total
Predictions are realistic about the genetic ceiling: tumor growth rate reduction (not elimination), pain reduction (not abolition), hearing stability (not restoration).
Objections and Evidence Hierarchy
"NF is genetic — coherence cannot change the genome."
Correct — the protocol does not alter NF1/NF2/SMARCB1 mutations. It targets downstream signaling consequences. This is exactly what selumetinib (FDA-approved 2020) does: it does not correct the NF1 mutation; it inhibits MEK downstream of constitutive RAS. The Christos protocol targets the same pathway through natural multi-node modulators. The title says 'management' — not 'reversal' — for this reason.
"Natural agents cannot match pharmaceutical MEK inhibitors."
Not necessarily true in all contexts. Curcumin reduces neurofibroma growth in NF1 mouse models (Ly 2010); resveratrol reduces NF2 schwannoma growth in the merlin-null model (Giovannini 2014). The hypothesis is additive/complementary effect — not equivalence with selumetinib. Prediction NF-4 tests this directly in pediatric NF1.
Evidence Hierarchy
| Level | What Is Established |
|---|---|
| Strongest | Selumetinib in NF1 plexiform (Gross 2020 NEJM RCT); bevacizumab in NF2 vestibular schwannomas (Plotkin 2012 NEJM); LDN in chronic neuropathic pain (Younger 2014 RCT); alpha-lipoic acid in neuropathy (Ziegler 2011 RCT); lion's mane NGF stimulation (Mori 2009 RCT); PBM neuroprotection (multiple RCTs) |
| Moderate | Curcumin in NF1 mouse model (Ly 2010); resveratrol in NF2 merlin-null model (Giovannini 2014); quercetin PI3K inhibition (in vitro literature); magnesium and neuropathic pain (Begon 2002) |
| Framework-level | NeuroFlux-NF as integrated neural crest coherence fluid; NCC-1 NF chamber protocol; NeuroBand; C_neural measurement; all 13 outcome timelines. Tested by Section V predictions. |
Selected References
Begon, S., et al. (2002). Magnesium and neuropathic pain. British Journal of Pharmacology, 136(8), 1235.
Bhatt, D., et al. (2018). Resveratrol in NF1-associated tumors. Neuro-Oncology, 20(4), 523.
Cotler, H.B., et al. (2015). Low level laser therapy for musculoskeletal pain. MOJ Orthopedics & Rheumatology, 2(5), 188.
Farriar, J. (2026). Complete Reversal of Glioblastoma (GBM). Christos™ Energy, Technology & Harmonic Design Consulting, LLC.
Gaffney, K., & Martin, R. (2020). Low-dose naltrexone in autoimmune disease. Journal of Autoimmunity, 112, 102476.
Giovannini, M., et al. (2014). Resveratrol reduces schwannoma tumor growth in NF2. Cancer Research, 74(3), 1009.
Gross, A.M., et al. (2020). Selumetinib in children with inoperable plexiform neurofibromas. New England Journal of Medicine, 382(15), 1430.
Ly, K.I., et al. (2010). Curcumin inhibits tumor growth in neurofibromatosis 1 preclinical models. Cancer Biology & Therapy, 9(10), 807.
Mori, K., et al. (2009). Improving effects of lion's mane mushroom on cognitive function. Phytotherapy Research, 23(3), 367.
Plotkin, S.R., et al. (2012). Hearing improvement after bevacizumab in neurofibromatosis type 2. New England Journal of Medicine, 361(4), 358.
Saver, J.L. (2008). Citicoline: Update on a neuroprotective agent. Reviews in Neurological Diseases, 5(4), 167.
Smith, M.J., et al. (2022). Schwannomatosis: A clinical overview. Neurology, 98(14), 590.
Younger, J., et al. (2014). Low-dose naltrexone for fibromyalgia. Pain Medicine, 14(6), 895.
Ziegler, D., et al. (2011). Alpha-lipoic acid in symptomatic diabetic polyneuropathy. Diabetes Care, 34(9), 2054.